WallStreetZen

NASDAQ: NEO
Neogenomics Inc Stock Forecast, Predictions & Price Target

Analyst price target for NEO

Based on 7 analysts offering 12 month price targets for Neogenomics Inc.
Min Forecast
$46.00-1.84%
Avg Forecast
$59.00+25.91%
Max Forecast
$65.00+38.71%

Should I buy or sell NEO stock?

Based on 8 analysts offering ratings for Neogenomics Inc.
Strong Buy
Strong Buy
4 analysts 50%
Buy
3 analysts 37.5%
Hold
1 analysts 12.5%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

NEO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
Anonymous
Morgan Stanley
Strong BuyMaintains$58.00+23.77%2021-08-09
Goldman Sachs
Bottom 6%
6
Strong BuyInitiates Coverage On$55.00+17.37%2021-06-03
Morgan Stanley
Top 22%
79
Strong BuyMaintains$64.00+36.58%2021-02-25
Needham
Top 7%
94
BuyAssumes$65.00+38.71%2021-02-25
Raymond James
Top 22%
79
HoldDowngradesN/AN/A2021-02-25
Truist Securities
Top 3%
98
Strong BuyInitiates Coverage On$65.00+38.71%2021-01-28
SVB Leerink
Top 6%
95
BuyMaintains$60.00+28.04%2021-01-08
Needham
Top 3%
98
BuyMaintains$46.00-1.84%2020-10-28

1 of 1

Forecast return on equity

Is NEO forecast to generate an efficient return?
Company
-2.57%
Industry
43.45%
Market
1,975.18%
NEO's Return on Equity is forecast to be low in 3 years (-2.57%); analysts are not confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is NEO forecast to generate an efficient return on assets?
Company
-1.55%
Industry
11%
Market
951.37%
NEO is forecast to generate lower Return on Assets (-1.55%) than the US Diagnostics & Research industry average (11%)
Forecast

NEO earnings per share forecast

What is NEO's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.34-155.74%
Avg 2 year Forecast
-$0.30-149.18%
Avg 3 year Forecast
-$0.24-139.34%

NEO revenue forecast

What is NEO's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$500.0M+2.31%
Avg 2 year Forecast
$582.1M+19.11%
Avg 3 year Forecast
$672.1M+37.52%
NEO's revenue is forecast to grow at a rate of 9.35% per year, which is not exceptional
Forecast

NEO revenue growth forecast

How is NEO forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
9.35%
Industry
6.76%
Market
14.66%
NEO's revenues are forecast to grow faster (9.35% per year) than the US Diagnostics & Research industry average (6.76%)
Forecast
NEO's revenues are forecast to grow slower (9.35% per year) than the US market average (14.66%)
Forecast

Neogenomics Stock Forecast FAQ

Is Neogenomics Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: NEO) stock is to Strong Buy NEO stock.

Out of 8 analysts, 4 (50%) are recommending NEO as a Strong Buy, 3 (37.5%) are recommending NEO as a Buy, 1 (12.5%) are recommending NEO as a Hold, 0 (0%) are recommending NEO as a Sell, and 0 (0%) are recommending NEO as a Strong Sell.

What is NEO's earnings growth forecast for 2021-2023?

(NASDAQ: NEO) Neogenomics's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 7.8%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 22.98%.

Neogenomics's earnings in 2021 is $71,733,000.On average, 4 Wall Street analysts forecast NEO's earnings for 2021 to be $-41,757,547, with the lowest NEO earnings forecast at $-46,670,199, and the highest NEO earnings forecast at $-31,932,242. On average, 4 Wall Street analysts forecast NEO's earnings for 2022 to be $-36,844,894, with the lowest NEO earnings forecast at $-52,811,015, and the highest NEO earnings forecast at $-23,335,100.

In 2023, NEO is forecast to generate $-29,475,915 in earnings, with the lowest earnings forecast at $-29,475,915 and the highest earnings forecast at $-29,475,915.

What is NEO's revenue growth forecast for 2021-2023?

(NASDAQ: NEO) Neogenomics's forecast annual revenue growth rate of 9.35% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 6.76%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.66%.

Neogenomics's revenue in 2021 is $488,698,000.On average, 4 Wall Street analysts forecast NEO's revenue for 2021 to be $61,408,279,816, with the lowest NEO revenue forecast at $61,165,717,596, and the highest NEO revenue forecast at $61,734,848,395. On average, 4 Wall Street analysts forecast NEO's revenue for 2022 to be $71,491,744,828, with the lowest NEO revenue forecast at $69,914,414,908, and the highest NEO revenue forecast at $72,968,856,637.

In 2023, NEO is forecast to generate $82,539,809,171 in revenue, with the lowest revenue forecast at $82,122,110,887 and the highest revenue forecast at $82,957,507,454.

What is NEO's forecast return on assets (ROA) for 2021-2023?

(NASDAQ: NEO) forecast ROA is -1.55%, which is lower than the forecast US Diagnostics & Research industry average of 11%.

What is NEO's Price Target?

According to 7 Wall Street analysts that have issued a 1 year NEO price target, the average NEO price target is $59.00, with the highest NEO stock price forecast at $65.00 and the lowest NEO stock price forecast at $46.00.

On average, Wall Street analysts predict that Neogenomics's share price could stay at $59.00 by Aug 9, 2022. The average Neogenomics stock price prediction forecasts a potential downside of N/A from the current NEO share price of $46.86.

What is NEO's Earnings Per Share (EPS) forecast for 2021-2023?

(NASDAQ: NEO) Neogenomics's current Earnings Per Share (EPS) is $0.61. On average, analysts forecast that NEO's EPS will be $-0.34 for 2021, with the lowest EPS forecast at $-0.38, and the highest EPS forecast at $-0.26. On average, analysts forecast that NEO's EPS will be $-0.30 for 2022, with the lowest EPS forecast at $-0.43, and the highest EPS forecast at $-0.19. In 2023, NEO's EPS is forecast to hit $-0.24 (min: $-0.24, max: $-0.24).

What is NEO's forecast return on equity (ROE) for 2021-2023?

(NASDAQ: NEO) forecast ROE is -2.57%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.